<DOC>
	<DOCNO>NCT00351702</DOCNO>
	<brief_summary>Title : Evaluation efficacy two different preventive therapy regimens tuberculosis HIV infect person Phase : Phase III trial Population : 650 HIV positive patient without tuberculosis Number site : Three 1 . Tuberculosis Research centre , Chennai 2 . Government General Hospital , Chennai 3 . Government Rajaji Hospital , Madurai Study Duration : 36 month Study Objectives : To compare efficacy two TB preventive therapy regimens reduce incidence tuberculosis mortality among HIV-infected person Study Design : The study two-armed prospective randomize clinical trial among HIV- positive patient without active tuberculosis . Enrolled patient assign one two unsupervised self-administered treatment regimen i.e . EH 6 month INH alone 3 year . At end 3-year follow-up , incidence TB overall mortality compare group . Study Endpoints : The primary end point study development tuberculosis secondary endpoint include adverse drug reaction mortality rate .</brief_summary>
	<brief_title>Preventive Therapy Tuberculosis HIV Infected Persons</brief_title>
	<detailed_description>Study population enrollment : All HIV positive patient seek care one study center , age 15 year , suffer serious illness , non-pregnant , TB rule use enhanced screening process , enrol study . The consent form prophylaxis trial read patient local language write consent obtain willing patient Randomization Dosing : All patient enrol prevention trial randomize one study group use permuted block randomization scheme four . Stratification do Mantoux reading ( &gt; 5mm â‰¤5mm ) . The group assignment list generate centrally start trial sequentially number sealed envelope contain study group assign prepared independently . At initiation prophylaxis , patient counsel importance take drug regularly . Patients ask return empty packet well unused tablet monthly visit . The treatment regimens study group follow : 1 . Ethambutol ( 800 mg ) Isoniazid ( 300 mg ) daily six month , self-administered , collect fifteen day . 2 . Isoniazid ( 300 mg ) daily 3 year fortnightly collection drug Subjects study group receive 10 mg Pyridoxine daily treatment .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>1 . Age &gt; 15 year 2 . HIV positivity ( 2 different ELISA test blood sample ) 3 . Living Chennai Madurai within define area intake 25 km radius . 4 . Likely remain area least three year start treatment 5 . The patient judge cooperative willing fortnightly attendance next 3 year 6 . Is agreeable home visit 7 . No major complication HIV disease like encephalopathy , renal hepatic disease end stage disease . 8 . No medical condition might interfere management like diabetes , convulsion , serious cardiac disease . 9 . Patients fulfill laboratory criterion ( hemoglobin &gt; 7.0g/l , granulocyte count &gt; 11,000/l , platelet count &gt; 1 lakh/l . serum alanine amino transferase concentration &lt; 2.5 time upper limit normal serum creatinine concentration &lt; 1.1 mg % , random blood sugar &lt; 140 mg % ) enrol study . 1 . Resides outside area intake . 2 . Pregnancy lactation . 3 . Patients major psychiatric illness severe depression 4 . Major complication HIV disease like encephalopathy , renal hepatic disease end stage disease 5 . Serious cardiac disease ( CCF , IHD ) , uncontrolled diabetes mellitus , convulsion , cancer , moribund state 6 . Previous antituberculosis treatment 1 month 7 . Patients ART</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Preventive therapy</keyword>
</DOC>